Serum specific IgG response to toluene diisocyanate-tissue transglutaminase conjugate in toluene diisocyanate-induced occupational asthmatics

Ann Allergy Asthma Immunol. 2014 Jul;113(1):48-54. doi: 10.1016/j.anai.2014.04.022.

Abstract

Background: Tissue transglutaminase (tTG) is a post-translational modifying enzyme located in airway epithelial cells. A potential contribution of serum specific IgG (sIgG) to tTG in airway inflammation of toluene diisocyanate (TDI)-induced occupational asthma (OA) has been suggested.

Objective: To prepare a TDI-tTG conjugate and detect serum specific antibodies in sera of patients with TDI-OA to understand this mechanism.

Methods: Ninety-nine patients with TDI-OA, 76 asymptomatic exposed controls, 208 patients with non-OA, and 74 unexposed controls were enrolled for this study. The TDI-tTG conjugate was prepared and confirmed by a native gel. Serum sIgG and/or sIgE antibodies to tTG, TDI-tTG, TDI conjugated to human serum albumin, cytokeratin 19, and serum cytokine levels, such as interleukin-8, transforming growth factor-β1, and tissue inhibitor of metalloproteinase-1, were measured by enzyme-linked immunosorbent assay. The level of interleukin-8 produced from airway epithelial cells (A549) treated with tTG was evaluated to investigate the inflammatory effect of tTG and TDI-tTG.

Results: In the TDI-OA group, the prevalence of serum sIgG to TDI-tTG (17.2%) was higher than that of sIgG to tTG (11.1%), which were significantly higher than those of the 3 control groups (P < .05 for all groups). TDI-exposed subjects with high levels of serum sIgG to TDI-tTG had a high prevalence of sIgG to cytokeratin 19 and higher serum levels of transforming growth factor-β1 and tissue inhibitor of metalloproteinase-1. The tTG and TDI-tTG dose-dependently increased interleukin-8 production from A549 cells.

Conclusion: These findings suggest that TDI exposure in the workplace binds to tTG to form a conjugate that can induce serum sIgG antibody production, airway inflammation, and airway remodeling in patients with TDI-OA.

MeSH terms

  • Adult
  • Airway Remodeling / drug effects*
  • Airway Remodeling / immunology
  • Asthma, Occupational / blood*
  • Asthma, Occupational / chemically induced
  • Asthma, Occupational / enzymology
  • Asthma, Occupational / immunology
  • Case-Control Studies
  • Cell Line, Tumor
  • Dose-Response Relationship, Immunologic
  • Female
  • Humans
  • Immunoglobulin E / blood*
  • Immunoglobulin G / blood*
  • Interleukin-8 / blood
  • Interleukin-8 / immunology
  • Keratin-19 / chemistry
  • Male
  • Middle Aged
  • Serum Albumin / chemistry
  • Tissue Inhibitor of Metalloproteinase-1 / blood
  • Tissue Inhibitor of Metalloproteinase-1 / immunology
  • Toluene 2,4-Diisocyanate / adverse effects*
  • Toluene 2,4-Diisocyanate / chemistry
  • Toluene 2,4-Diisocyanate / immunology
  • Transforming Growth Factor beta1 / blood
  • Transforming Growth Factor beta1 / immunology
  • Transglutaminases / adverse effects*
  • Transglutaminases / chemistry
  • Transglutaminases / immunology

Substances

  • Immunoglobulin G
  • Interleukin-8
  • Keratin-19
  • Serum Albumin
  • TIMP1 protein, human
  • Tissue Inhibitor of Metalloproteinase-1
  • Transforming Growth Factor beta1
  • Toluene 2,4-Diisocyanate
  • Immunoglobulin E
  • Transglutaminases